Clinical TrialMay 7, 2026, 08:02 AM
ALX Oncology Evorpacept Phase 1b/2 trial shows 100% cORR in high CD47 mBC
AI Summary
ALX Oncology announced positive data from exploratory analyses of its Phase 1b/2 clinical trial for evorpacept in combination with zanidatamab for heavily pre-treated HER2-positive metastatic breast cancer. The findings, presented at ESMO Breast Cancer 2026, showed a 100% confirmed objective response rate and significantly longer median progression-free survival (22.1 months) in patients with high CD47 expression. These results further validate a biomarker-driven development strategy for evorpacept. The company also scheduled a webcast for May 8, 2026, to discuss Q1 2026 financial results and the trial data.
Key Highlights
- Evorpacept Phase 1b/2 trial showed 100% confirmed objective response rate (cORR) in HER2-positive mBC patients with high CD47 expression (n=5/5).
- Patients with high CD47 expression had a median progression-free survival (mPFS) of 22.1 months, compared to 3.4 months for low CD47 expression.
- Median duration of response (mDOR) was 20.2 months in patients with high CD47 expression.
- Overall cORR among all 24 patients was 33%, with an mPFS of 3.6 months.
- Patients with centrally confirmed HER2-positive disease (n=10) had a cORR of 60% and mPFS of 8.3 months.
- ALX Oncology will host a webcast on May 8, 2026, to report first quarter 2026 financial results and discuss trial data.